Glucotrack is advancing LT-100 while its ai² platform applies pharmaceutical Due Diligence across more than 12,000 late-stage programs. The priorities matter to investors because the update links near-term clinical development with a stated model of discovering, advancing and monetizing therapeutic assets, while Glucotrack Technologies continues its diabetes technology work.

Key Highlights

  • A clinical protocol for LT-100 has been submitted for regulatory review.
  • Conversion of Series A convertible preferred stock remains subject to Nasdaq requirements and other conditions.
  • The ai² network applies standard pharmaceutical due diligence across more than 12,000 late-stage pharmaceutical programs.

LT-100 Moves Toward Clinical Study

Glucotrack (NASDAQ: GCTK) Technologies remains a wholly owned subsidiary. LT-100 is a biologic programme being developed for osteoarthritis knee pain. The proposed trial will assess safety and efficacy after subcutaneous administration against the historical intradermal regimen. Glucotrack completed its strategic Business combination on July 14, and the conversion process for Series A convertible preferred stock remains subject to Nasdaq requirements and other conditions.

ai² Platform Broadens Development Priorities

The ai² platform combines asset identification, talent development and an accelerator focused on emerging technology, data and innovation initiatives. Its pipeline work involves university participants and preliminary business development discussions around selected opportunities. The stated operating model is to discover near-term therapeutic opportunities, advance them through development and pursue monetization before completion of registration trials.